BenzingaOctober 5, 2026 at 5:04 AM NY22 Days Ago
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
